GlassScriptPhysician profile
Humayun Ashraf
NPI 1184980765
$13,515.13
in general payments reported to CMS, 2019-2025
37 companies · $2,621 in 2025
The $2,621 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $1,374 · 2021: $240 · 2022: $96.50 · 2023: $1,223 · 2024: $7,307 · 2025: $2,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,611 · Food and Beverage: $3,967 · Travel and Lodging: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,611.29 |
| Food and Beverage | $3,966.72 |
| Travel and Lodging | $1,572.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,299.54 | 2024-2025 | |
| Veran Medical Technologies, INC. | $968.16 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $896.14 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Glaxosmithkline, LLC. | $892.81 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $688.58 | 2019-2025 | Airsupra, Breztri, Fasenra |
| United Therapeutics Corporation | $287.41 | 2021-2025 | Tyvaso |
| Genentech USA, INC. | $229.25 | 2019-2025 | Xolair |
| Actelion Pharmaceuticals US, INC. | $223.58 | 2019-2024 | Uptravi, Opsumit |
| Grifols USA, LLC | $214.27 | 2023-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $162.13 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $153.92 | 2019-2020 | |
| Inspire Medical Systems, INC. | $121.25 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $113.75 | 2020-2025 | Dupixent |
| Amgen INC. | $100.00 | 2024-2025 | Tezspire, Tavneos |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $90.68 | 2024 | |
| Inari Medical, INC. | $89.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $88.30 | 2020-2024 | |
| Harmony Biosciences LLC | $88.29 | 2020-2023 | Wakix |
| Verona Pharma, INC. | $88.01 | 2025 | Ohtuvayre |
| Philips North America LLC | $78.72 | 2024-2025 | (8874) Incourage, Vest Therapy Und, (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $74.01 | 2020-2025 | Glassia |
| Zoll Respicardia, INC. | $57.86 | 2024-2025 | Remede System |
| Pfizer INC. | $50.70 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $45.05 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $43.00 | 2019-2020 | |
| Sanofi US Services INC. | $39.45 | 2024 | |
| Viatris Specialty LLC | $36.14 | 2025 | Yupelri |
| Insmed, INC. | $32.99 | 2024-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $30.41 | 2023-2024 | Nuzyra |
| Abbvie INC. | $29.03 | 2023 | Avycaz |
| Axsome Therapeutics, INC. | $21.83 | 2023 | Sunosi |
| Electromed, INC. | $21.22 | 2023 | Smartvest |
| Hospira, INC. | $17.79 | 2024 | |
| Baxter Healthcare | $17.72 | 2020 | |
| Horizon Therapeutics Plc | $13.64 | 2019 | |
| Resmed Corp | $13.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humayun Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.